ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Not Too Late to Own ANI Pharmaceuticals (ANIP), Guggenheim Says
March 6, 2015 8:47 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $79 price target on ANI Pharmaceuticals (NASDAQ: ANIP) following meetings with management.
Chen commented, "We remain positive on ANIP shares after hosting meetings with CEO, Art Przybyl, and CFO, Charlotte Arnold on 3/4/15. Although ANIP... More
ANI Pharma (ANIP) Acquires Approved Flecainide Acetate ANDA
March 5, 2015 8:45 AM ESTANI Pharma (NASDAQ: ANIP) has acquired the approved abbreviated new drug application ("ANDA") for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals (NYSE: TEVA). According to IMS Health, the overall market for this product... More
